Workflow
PCSK9抑制剂
icon
Search documents
“过节式”作息或带来心脑血管疾病风险。专家:降压药不会让血管变薄,应规律服药
3 6 Ke· 2025-10-09 02:37
时值十一长假,人们的饮食、作息也切换成"过节式",长途跋涉、舟车劳顿、走亲访友、过度饮酒、暴 饮暴食、熬夜刷剧玩游戏成为常态,原有的生活节奏被打乱,带来的健康风险也不容忽视。 在十一假期期间大快朵颐、熬夜娱乐之余,预防及减轻心脑血管疾病的带来危害也成为国人假日期间所 面临的健康挑战之一。 近几年,心脑血管疾病已经成为危害国人健康的主要"杀手"之一。在心脑血管疾病中,冠心病尤为凶 险,中国国家心血管病中心2023年发布的数据表明,我国冠心病患者已超过1100万,且每年以约2.5% 的速度增长。 冠心病全称冠状动脉粥样硬化性心脏病,根据我国最新统计数据,冠心病在我国的患病率和死亡率呈现 持续上升趋势,在人口老龄化的大形势下,该趋势预计进一步加剧。与此同时,也需要警惕近年来冠心 病发病的年轻化趋势。 "近年来,冠心病发病出现年轻化趋势,这与年轻人不健康的生活方式以及当今社会、环境、心理等多 个因素均密切相关。可以说,冠心病是一个影响国民健康和生命质量的重大公共卫生问题,亟需全社会 和大家的重视和管理。"近日,北京大学第一医院副院长李建平在接受时代周报记者专访时指出。 李建平强调,冠心病年轻化趋势主要源于不健康生活方 ...
明明已经很瘦了,怎么体检胆固醇超标啊?难道真是鸡蛋吃多了?
Yang Shi Xin Wen· 2025-09-14 10:10
Group 1 - Cholesterol is an essential substance for the human body, playing a critical role in synthesizing hormones and vitamin D, and forming cell membranes [3][4] - Cholesterol levels can be influenced by both internal factors (genetics, diseases) and external factors (lifestyle habits such as diet and exercise) [4] - There are two types of cholesterol: high-density lipoprotein (HDL-C) known as "good cholesterol" and low-density lipoprotein (LDL-C) known as "bad cholesterol" [5][6] Group 2 - High levels of LDL-C can lead to serious health issues such as coronary heart disease and stroke, while HDL-C helps to remove excess cholesterol from the bloodstream [6][7] - It is important to assess cholesterol health through a comprehensive analysis of various blood lipid indicators, not just total cholesterol [8][10] - Individual cholesterol levels can vary based on personal health history, age, and lifestyle, making it essential to consider these factors when evaluating cholesterol [7][8] Group 3 - Dietary recommendations for lowering cholesterol include increasing intake of whole grains and high-quality fats while avoiding saturated and trans fats [10][12][14] - Regular physical activity is advised, with recommendations for at least 150 minutes of moderate-intensity aerobic exercise per week [22] - If lifestyle changes are insufficient, medication may be necessary, with common options including statins and cholesterol absorption inhibitors [24][25]
这款进口药退出!PCSK9药物竞争加剧 降脂药下个风口剑指何方?|财经解药
Xin Lang Cai Jing· 2025-08-07 10:15
Core Insights - Sanofi has confirmed the cessation of the promotion of its PCSK9 inhibitor, Alirocumab, in the Chinese market due to global supply issues and a strategic upgrade in its cardiovascular product line [2][3] - The exit of Alirocumab from the market has opened opportunities for domestic pharmaceutical companies to enter the PCSK9 inhibitor space [1][3] Industry Overview - PCSK9 inhibitors are considered a milestone in lipid-lowering therapies, with significant implications for managing high LDL cholesterol levels, which are primarily influenced by genetic factors [1][3] - The understanding of lipoprotein(a) [Lp(a)] in cardiovascular diseases has led to increased interest in developing new lipid-lowering drugs targeting this specific marker [1][7] Market Dynamics - The market for lipid-lowering medications is competitive, with established statin drugs and newer PCSK9 inhibitors being used in combination for optimal patient outcomes [4][5] - There are currently seven approved PCSK9 inhibitors in China, including both imported and domestic products, with ongoing developments from various companies [5][6] Emerging Opportunities - Companies are actively pursuing the development of alternative medications in light of Alirocumab's market exit, indicating a robust interest in the PCSK9 inhibitor segment [3][6] - The market is also seeing advancements in therapies targeting Lp(a), with several multinational corporations engaged in clinical trials for new drugs aimed at lowering Lp(a) levels [7]
专家:降血脂是一场“持久战” 不可擅自停药
Zhong Guo Xin Wen Wang· 2025-06-10 01:50
Core Viewpoint - The increasing levels of blood lipids and the prevalence of dyslipidemia among Chinese individuals highlight the need for better management of low-density lipoprotein cholesterol (LDL-C) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) [1][2][3] Group 1: Importance of LDL-C Management - LDL-C is identified as a major contributor to high blood lipids and a significant risk factor for ASCVD, emphasizing the importance of lowering LDL-C levels to reduce morbidity and mortality associated with cardiovascular diseases [1][2] - Experts advocate for a targeted and stratified approach to blood lipid management, stressing the need for public awareness and education regarding the significance of monitoring LDL-C levels [1][2] Group 2: Lifestyle and Treatment Recommendations - Lifestyle modifications, including dietary control and physical activity, are crucial as approximately two-thirds of LDL-C comes from external sources [2][3] - Regular monitoring and risk assessment of LDL-C levels are essential, especially for high-risk populations, who may require more stringent control and treatment of underlying conditions like hypertension and diabetes [2][3] Group 3: Misconceptions and Long-term Treatment - There is a prevalent misconception among patients that achieving target LDL-C levels means discontinuing medication, which can lead to adverse cardiovascular events [3][4] - Continuous and scientifically guided lipid-lowering therapy is vital for stabilizing LDL-C levels and preventing cardiovascular incidents, particularly in patients with existing ASCVD [3][4] Group 4: Current Treatment Landscape - The treatment rates and achievement rates for lipid-lowering therapy among ASCVD patients need improvement, with many still relying on traditional statin medications [4] - While statins are effective, some patients may have contraindications, necessitating the use of non-statin alternatives for optimal LDL-C management [4]
死亡列车:每5人就有2人上车,但你可以说不
Hu Xiu· 2025-05-19 08:01
Group 1 - The article discusses the ethical dilemma of the "Trolley Problem" and its application to real-world issues, particularly in the context of cardiovascular diseases [2][4][5] - It highlights that cardiovascular diseases are the leading cause of death globally, with nearly 20 million deaths annually, and in China, approximately 4.58 million deaths occur each year due to these diseases [8][9] - The article emphasizes the significant increase in cardiovascular disease cases over the past 40 years, primarily due to aging and unhealthy lifestyles [10][11] Group 2 - The main risk factors for cardiovascular diseases include high blood pressure, high cholesterol, diabetes, obesity, and smoking, with lifestyle choices being the primary contributor [11][21] - The article identifies atherosclerosis as the leading cause of cardiovascular diseases, which is a chronic process that can take decades to develop [16][18] - It states that lowering LDL-C (low-density lipoprotein cholesterol) is crucial for preventing atherosclerosis and related cardiovascular events, with a direct correlation between LDL-C levels and cardiovascular risk [22][30] Group 3 - The article presents practical recommendations for managing cardiovascular health, including setting LDL-C targets based on risk levels and emphasizing lifestyle changes [36][41] - It discusses the importance of early intervention and the need for individuals to take responsibility for their health, suggesting that proactive measures can significantly reduce the risk of cardiovascular diseases [33][54] - The article concludes by urging individuals to recognize their health status and take action to prevent becoming "passengers" on the metaphorical "Blue Sky" train of cardiovascular disease [56][58]
研判2025!中国降脂药行业产业链、市场现状、重点企业及未来前景分析:新型降脂药物研发上市加速,行业规模不断扩容[图]
Chan Ye Xin Xi Wang· 2025-05-13 01:20
Industry Overview - The cholesterol-lowering drug industry is crucial for preventing and treating cardiovascular diseases, with a growing patient population due to aging and increasing rates of dyslipidemia [1][8] - The prevalence of dyslipidemia among the elderly is high, with 47% of individuals over 60 affected, while the rate among those aged 18 and above has risen from 18.6% in 2002 to 35.6% in 2023 [8][10] Market Development - The cholesterol-lowering drug market in China is projected to grow from CNY 252.94 billion in 2023 to CNY 265.95 billion in 2024, despite a slowdown due to national procurement policies [10][20] - Sales distribution shows that 57% of sales come from hospitals, while 43% are from retail markets [10] Drug Categories - Cholesterol-lowering drugs are categorized into statins, fibrates, niacin, bile acid sequestrants, PCSK9 inhibitors, and monoclonal antibodies targeting angiopoietin-like protein 3 [3][12] - Statins dominate the market with a 76.58% share, but innovative drugs like PCSK9 inhibitors are gaining traction [12][22] Competitive Landscape - The market is experiencing significant changes, with foreign companies like Pfizer and Sanofi leading the high-end market, while local firms like Yuyuan Health and Jingxin Pharmaceutical focus on mid to low-end markets [14][16] - Competition is shifting from price to efficacy, safety, and brand service, with an expected increase in market concentration through mergers and international collaborations [14][22] Company Highlights - Jingxin Pharmaceutical focuses on the development and sales of statins and is expanding into combination therapies and new drug targets [16] - Yuyuan Health has developed a PCSK9-targeting siRNA drug, YKYY015, which is in clinical trials and has received IND approval in the U.S. [18] - The revenue of Yuyuan Health is projected to decline by 9.9% in 2024, with cardiovascular drug sales down by 20.73% [18] Future Trends - The market for cholesterol-lowering drugs is expected to continue expanding due to an increasing patient population and unmet treatment needs, with projections indicating a compound annual growth rate above a certain percentage [20][21] - Innovation in drug development is on the rise, with companies investing in new targets like Lp(a) and PCSK9 inhibitors, enhancing treatment options for patients [21][22]
靶向PCSK9基因,真能一劳永逸降血脂?
Ke Ji Ri Bao· 2025-04-22 01:22
Core Viewpoint - A new study published in Nature Medicine introduces a targeted epigenetic editor (PCSK9-EE) that significantly and sustainably lowers low-density lipoprotein cholesterol (LDL-C) levels in transgenic mice and crabs monkeys, raising hopes for lifelong lipid reduction in hyperlipidemia patients [1][6]. Group 1: Research Findings - The PCSK9-EE can almost completely suppress PCSK9 levels in the bloodstream of transgenic mice for at least one year after a single administration, while in crabs monkeys, it can reduce PCSK9 protein levels by approximately 90% and LDL-C levels by up to 70% for at least three months [5]. - PCSK9-EE operates through epigenetic modification of DNA methylation, silencing the expression of the PCSK9 gene in the liver, thus lowering LDL-C levels [4]. Group 2: Health Implications - Cardiovascular diseases, including coronary heart disease and stroke, are closely linked to elevated LDL-C levels, which have risen in global health risk rankings from the 14th to the 8th position between 1990 and 2019 [2]. - Factors contributing to high LDL-C levels include poor lifestyle choices, genetic predisposition, and age-related changes, which increase the risk of cardiovascular diseases [3]. Group 3: Current Treatment Landscape - Traditional lipid-lowering medications, primarily statins, have limitations, including inadequate LDL-C level control and potential side effects like muscle pain and elevated liver enzymes [4]. - Newer PCSK9 inhibitors have shown significant advantages in lipid management and are already in clinical use in China, with options for less frequent dosing [4]. Group 4: Future Considerations - Despite promising animal study results, PCSK9-EE has not yet entered clinical trials, and its long-term efficacy and safety in humans remain to be validated [6][7]. - The potential for PCSK9-EE to achieve "lifelong lipid reduction" is considered premature, with experts suggesting a more cautious interpretation of its benefits until further research is conducted [6][7].
出海不顺的信达生物利润转正,单靠国内市场能维持吗?
Xin Lang Cai Jing· 2025-03-27 13:19
Core Viewpoint - The article highlights the increasing trend of innovative drug companies in China achieving profitability through product sales rather than one-time business development (BD) transactions, with examples including Innovent Biologics and others focusing on both domestic and international markets [1][2]. Group 1: Company Performance - On March 26, 2024, Innovent Biologics reported a revenue of 9.422 billion yuan, a year-on-year increase of 51.8%, and reduced its annual loss from 1.028 billion yuan to 94.631 million yuan, a decrease of 90.8% [2]. - The company achieved its first positive Non-IFRS profit and Non-IFRS EBITDA of 332 million yuan and 412 million yuan, respectively [2]. - The stock price of Innovent Biologics surged by 17.41% to close at 45.850 HKD per share, with a market capitalization of 75.11 billion HKD [3]. Group 2: Revenue Breakdown - Product revenue reached 8.228 billion yuan, up 43.6%, while licensing fee income doubled from 447 million yuan to 1.1 billion yuan [4]. - Despite significant revenue growth, the company still could not cover operational costs and expenses solely from sales revenue in 2024, indicating reliance on increased licensing fee income for reduced losses [4][5]. Group 3: Future Prospects - Innovent Biologics anticipates improvement in 2025 as several drugs, including lung cancer and hematological malignancy treatments, have been approved for market entry [5]. - The company aims to achieve 20 billion yuan in product revenue by 2027 and has set a goal to have five pipelines enter global multi-center Phase III clinical trials by 2030 [2][5]. - The establishment of a cardiovascular and metabolic (CVM) division is underway, with a focus on diverse marketing strategies and building a consumer-facing brand image [6]. Group 4: Strategic Collaborations and Market Expansion - Innovent Biologics formed a strategic partnership with Meinian Health focusing on precise interventions for overweight patients with fatty liver [7]. - The company has engaged in BD transactions, including a notable deal with Roche for the exclusive rights to develop, produce, and commercialize IBI3009, a targeted ADC for small cell lung cancer, with an upfront payment of 80 million USD and potential milestone payments of up to 1 billion USD [7][8]. - Innovent plans to expand clinical research from China to key markets like the US, with ongoing studies for innovative therapies [8].